Tuesday, 17 February 2015

FREE Public Lecture on Cancer

Date: Tuesday 17 February
Time: 7-9pm

Venue: Bailey Allen Hall, Áras na Mac Léinn, NUI Galway
or you can donate on the night.
All proceeds are in aid of the following charities:
Irish Cancer Society, Cancer Care West, NBCRI and Galway Hospice.

Monday, 16 February 2015

New research to guide GP management for patients with multiple chronic illnesses

The new research recommends providing continuity of care with one named GP where possible, prioritising the aspects of care that matter most to patients (such as difficulties in physical functioning), and providing regular reviews of prescriptions. The study, recently published in the British Journal of Medicine, was led by researchers at the HRB Centre for Primary Care Research in the Royal College of Surgeons in Ireland.

The paper entitled, ‘Managing patients with multimorbidity in primary care' can be viewed online on the BMJ website at http://www.bmj.com/content/350/bmj.h176

Current clinical guidelines, which recommend best practice for GPs, tend to focus on single conditions which make decision making more challenging for those patients with several co-existing conditions.

Commenting on this publication, Graham Love, Chief Executive at the Health Research Board said,
‘It is very important that care for people with multimorbidity is organised and delivered based on best research evidence in order to improve the outcomes that really matter to patients. This review offers guidance for GPs to help support this process.’

More information is available from the press release on the RCSI website.

Recent Acquisitions


Located at 362.120994 McMU










Located at 610.72 GAR



Located at 616.132 BEE

Thursday, 12 February 2015

New breakthrough in stroke treatment

The clot retrieval procedure known as endo-vascular treatment was examined by researchers at the Royal College of Surgeons in Ireland and Beaumont Hospital in Dublin.
The study involved patients who had suffered an acute ischemic stroke, which is caused by a clot in the brain, and accounts for 80% of all strokes, and is published in the New England Journal of Medicine today.
It has been described as the most significant development in stroke treatment in the past two decades.
Positive outcomes for patients receiving the new “clot removal” treatment increased from 30% to 55%.
In many cases, instead of suffering major neurological disability, patients went home to resume their lives.
The overall mortality rate was reduced by 50%, from two in ten patients for standard treatment of care, to one in ten patients out of those who received the new treatment.
Professor David Williams, Associate Professor, one of the co-leads on the international study said:  "The results of this study represent the most significant development in stroke treatment in the past 20 years and will impact stroke care in Ireland and around the world.
“More than 10,000 people in Ireland are admitted to hospital with stroke annually and many of those who survive are left with significant disabilities.
“This treatment has the potential to improve survival rates and quality of life of more than 15 million people worldwide who suffer a stroke each year.
"The involvement of RCSI and Beaumont Hospital in this ground-breaking trial demonstrates the world-class expertise of clinical researchers here in Ireland," Professor Williams said.

Does the future hold a vaccine for type 1 diabetes?

Mikael Knip (lower row, on right side)

The next decade could see the development of a vaccine for type 1 diabetes, which could be given to all infants or those with a genetic susceptibility to the disease, according to a world expert.

A leading Professor of Paediatrics from Finland has suggested there is “increasing evidence” that the diabetic enterovirus may be a trigger for type 1 diabetes in children. If this is confirmed, Prof Mikael Knip of the University of Helsinki believes it may be possible to prevent about half of new cases with an anti-diabetes enterovirus vaccine.


Speaking to Irish Medical Times at the third annual 3U Partnership International Diabetes Conference, which took place at the RCSI in Dublin recently, Prof Knip accepted there was still a long way to go. “We will not have an anti-diabetic entero vaccine available within the next five to six years, but maybe within the next 10 years,” he stated.
The professor is currently the Principal Investigator for two extensive international multicentre studies on type 1 diabetes. One is TRIGR (Trial to Reduce IDDM in the Genetically at Risk) testing the hypothesis that weaning to an extensively hydrolysed formula will reduce the frequency of beta-cell autoimmunity and type 1 diabetes in children at risk. This trial is mainly funded by the National Institutes of Health (NIH).
Prof Knip addressed the 3U diabetes conference in a talk entitled ‘Current challenges in diabetes research’ on his work to date on the prevention of type 1 diabetes in children.

Wednesday, 11 February 2015

'Smart' insulin hope for diabetes

Scientists are hopeful that "smart" insulins which are undergoing trials could revolutionise the way diabetes is managed.
Instead of repeated blood tests and injections throughout the day to keep blood sugar in check, a single dose of smart insulin would keep circulating in the body and turn on when needed.
Animal studies show the technology appears to work - at least in mice.
Scientists plan to move to human trials soon, PNAS journal reports.
Experts caution that it will take years of testing before treatments could become a reality for patients.
Dr Danny Chou from the Massachusetts Institute of Technology has been testing a smart insulin that he and his colleagues developed in the lab.
It is a chemically modified version of regular, long-acting insulin.
It has an extra set of molecules stuck on the end that binds it to proteins that circulate in the bloodstream. While it is attached to these, the smart insulin is in its switched off mode.
When blood sugar rises, the smart insulin switches on - glucose locks on to the smart insulin and tells it to get to work.
Dr Chou said: "My goal is to make life easier and safer for diabetics.
View more on BBC/Health here

Tuesday, 10 February 2015

New Nursing & Midwifery Books


Located at 618.32686 NEO












Located at 617.0231 LeM












Located at 616.10082 CAM

New rules for eye-laser surgery

New guidelines have been drawn up for eye laser surgery amid growing concern over the use of hard-sell tactics in persuading consumers to undergo the procedure.


The guidelines from the Irish College of Ophthalmologists are voluntary, but the college says members who do not adhere to them will be refused membership.

Thousands of eye laser operations are carried out every year, the vast majority successfully. However, with complications arising in a minority of cases, the amount of litigation is increasing. At least 21 cases have been taken by individual consumers against a number of high street eye laser clinics since 2008.

Ophthalmologist and eye surgeon members of the college are increasingly concerned about the tactics used by some operators to market the procedures to customers and about the levels of pre- and aftercare provided.

“People may be led by the advertising used to think this is a trivial procedure with minimal complications,” says college president Billy Power.  “I’m amazed at the number of patients who say they never met their eye surgeon before the day of their laser operation. You wouldn’t do that with an ingrown toenail, and you certainly shouldn’t with an operation on your eye.”

The guidelines say communications with customers must not convey false information or omit material information, and must not “create unjustified expectations of results”: “Information on procedures must not trivialise the seriousness of surgery or minimise the potential risks.”

Surgeons must be registered with the Medical Council and have indemnity cover, and must be available for out-patient services and emergencies.

The information document about the surgery must be given to the patient at least 24 hours before the procedure is undertaken, to allow the patient discuss the risks and benefits involved.

Monday, 9 February 2015

Study indicates e-cigarettes harm lungs

E-cigarettes generate toxic chemicals similar to those found in tobacco and may harm the lungs and immune system, new research suggests.
The findings, from a study of mice, indicate that "vaping" is far from being a safe alternative to smoking tobacco.
In the experiments, mice exposed to e-cigarette fumes suffered mild damage to their lungs and became far more susceptible to respiratory infections.
Their immune responses to both viruses and bacteria were weakened by such an extent that some animals died.
Scientists also found that e-cigarette vapour contained "free radical" toxins similar to those found in cigarette smoke and air pollution.
Free radicals are highly reactive molecules that can damage DNA and cell membranes.
Professor Shyam Biswai, from Johns Hopkins University in the US, who led the research published in the online journal Public Library of Science ONE, said: "Our findings suggest that e-cigarettes are not neutral in terms of the effects on the lungs.
"We have observed that they increase the susceptibility to respiratory infections in the mouse models. This warrants further study in susceptible individuals, such as COPD (chronic obstructive pulmonary disorder) patients who have switched from cigarettes to e-cigarettes, or to new users of e-cigarettes who may have never used cigarettes."
Co-author Dr Thomas Sussan, also from Johns Hopkins, said: "E-cigarette vapour alone produced mild effects on the lungs, including inflammation and protein damage.
"However, when this exposure was followed by a bacterial or viral infection, the harmful effects of e-cigarette exposure became even more pronounced.

Friday, 6 February 2015

Health & Human Rights Conference, 6 February 2015


Under the President’s Ethics Initiative the Irish Centre for Human Rights and the College of Medicine, Nursing and Health Sciences at NUI Galway will host a one day meeting on Friday 6 February 2015 at the Aras Moyola Theatre, NUI Galway.

In the presence of President Michael D. Higgins, the meeting will examine how a human rights framework can inform ethical means to improve health and wellbeing and deliver healthcare fairly.


Click here for more information